Predictions
X4 Pharmaceuticals, Inc.
Start price
Target price
Perf. (%)
€1.14
28.04.24
28.04.24
-
28.04.25
28.04.25
-11.80%
07.05.24
07.05.24
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€1.83
28.04.24
28.04.24
-
28.04.25
28.04.25
8.96%
13.05.24
13.05.24
Fate Therapeutics Inc.
Start price
Target price
Perf. (%)
€3.53
28.04.24
28.04.24
-
28.04.25
28.04.25
17.56%
13.05.24
13.05.24
Could be worthwhile Investment >10% per year
Axcelis Technologies
Start price
Target price
Perf. (%)
€96.84
28.04.24
28.04.24
-
28.04.25
28.04.25
-8.69%
09.09.24
09.09.24
Probably not worthwhile Investment
Dependend from some customers or products
Bad culture
Little innovation
Centrotherm Photovoltaics AG
Start price
Target price
Perf. (%)
€4.15
27.04.24
27.04.24
-
27.04.25
27.04.25
3.61%
11.05.24
11.05.24
Heidelberger Druckmaschinen AG
Start price
Target price
Perf. (%)
€1.01
27.04.24
27.04.24
-
27.04.25
27.04.25
-
27.04.24
27.04.24
Newtek Business Services Inc.
Start price
Target price
Perf. (%)
€10.38
27.04.24
27.04.24
-
27.04.25
27.04.25
2.85%
05.09.24
05.09.24
Sangamo Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.50
27.04.24
27.04.24
-
27.04.25
27.04.25
61.12%
09.09.24
09.09.24
Tonix Pharmaceuticals Holding Corp.
Start price
Target price
Perf. (%)
€2.82
27.04.24
27.04.24
-
27.04.25
27.04.25
-
09.02.24
09.02.24
Enochian Biosciences Inc
Start price
Target price
Perf. (%)
€1.39
27.04.24
27.04.24
€1.00
27.04.25
27.04.25
-27.30%
11.05.24
11.05.24
Northern Data AG
Start price
Target price
Perf. (%)
€25.75
27.04.24
27.04.24
€50.00
27.04.25
27.04.25
1.75%
11.05.24
11.05.24
Revenue decline/stagnation expected
negative Cash Flow expected
Increased challenges to pay loans and raise capital
Higher risks for its business
Biodexa Pharmaceuticals Plc
Start price
Target price
Perf. (%)
€1.25
27.04.24
27.04.24
€2.00
27.04.25
27.04.25
-27.60%
11.05.24
11.05.24
Data Modul AG
Start price
Target price
Perf. (%)
€34.40
27.04.24
27.04.24
-
27.04.25
27.04.25
-3.49%
11.05.24
11.05.24
Probably not worthwhile Investment
Little Investments for future growth
Little known brand
Lower EBIT Margin than peer group